Adapting to the long pandemic.
作者信息
Davis John W
机构信息
BJUI Compass.
出版信息
BJUI Compass. 2022 Feb 16;3(2):95-98. doi: 10.1002/bco2.139. eCollection 2022 Mar.
Abstract
摘要
相似文献
1
Adapting to the long pandemic.适应长期的疫情。
BJUI Compass. 2022 Feb 16;3(2):95-98. doi: 10.1002/bco2.139. eCollection 2022 Mar.
2
Aquablation of the Prostate for Symptomatic Benign Prostatic Hyperplasia: 1-Year Results.经水囊前列腺切除术治疗有症状的良性前列腺增生：1年结果
J Urol. 2017 Jun;197(6):1565-1572. doi: 10.1016/j.juro.2017.01.056. Epub 2017 Jan 20.
3
Aquablation - image-guided robot-assisted waterjet ablation of the prostate: initial clinical experience.水刀消融术——影像引导下机器人辅助前列腺水刀消融术：初步临床经验
BJU Int. 2016 Jun;117(6):923-9. doi: 10.1111/bju.13358. Epub 2015 Nov 19.
4
Initial single centre experience of Aquablation of the prostate using the AquaBeam system with athermal haemostasis for the treatment of benign prostatic hyperplasia: 1-year outcomes.使用 Aquabeeam 系统行前列腺水刀消融术联合非热止血技术治疗良性前列腺增生的单中心初步经验：1 年随访结果。
World J Urol. 2021 Aug;39(8):3019-3024. doi: 10.1007/s00345-020-03534-z. Epub 2021 Jan 3.
5
6
Positron emission tomography for prostate, bladder, and renal cancer.用于前列腺癌、膀胱癌和肾癌的正电子发射断层扫描。
Semin Nucl Med. 2004 Oct;34(4):274-92. doi: 10.1053/j.semnuclmed.2004.06.004.
7
Transfusion rates after 800 Aquablation procedures using various haemostasis methods.800 次 Aquablation 手术中采用不同止血方法的输血率。
BJU Int. 2020 Apr;125(4):568-572. doi: 10.1111/bju.14990. Epub 2020 Jan 24.
8
Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer.前列腺的初始治疗可改善最终发展为去势抵抗性前列腺癌的男性的局部缓解。
BJU Int. 2013 Aug;112(4):E250-5. doi: 10.1111/bju.12169.
9
Peritoneal and port site seeding of an undiagnosed urothelial carcinoma of the bladder after robot-assisted laparoscopic prostatectomy.机器人辅助腹腔镜前列腺切除术后未诊断出的膀胱尿路上皮癌的腹膜和端口部位种植转移
Radiol Case Rep. 2020 Oct 6;15(12):2550-2553. doi: 10.1016/j.radcr.2020.09.024. eCollection 2020 Dec.
10
Incidental prostate cancer in patients with bladder urothelial carcinoma: comprehensive analysis of 1,476 radical cystoprostatectomy specimens.膀胱尿路上皮癌患者的偶发前列腺癌：1476 例根治性膀胱前列腺切除术标本的综合分析。
J Urol. 2013 Nov;190(5):1704-9. doi: 10.1016/j.juro.2013.05.034. Epub 2013 May 23.
本文引用的文献
1
Effect of advanced glycation end products on nocturia or sleep disorders: A longitudinal study.晚期糖基化终末产物对夜尿症或睡眠障碍的影响：一项纵向研究。
BJUI Compass. 2021 Oct 5;3(2):162-168. doi: 10.1002/bco2.114. eCollection 2022 Mar.
2
Prognostic impact of eligibility for adjuvant immunotherapy in locally advanced urothelial cancer.辅助免疫治疗对局部晚期尿路上皮癌的预后影响
BJUI Compass. 2021 Oct 8;3(2):146-153. doi: 10.1002/bco2.117. eCollection 2022 Mar.
3
Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma.质子泵抑制剂对晚期尿路上皮癌免疫治疗的预后影响
BJUI Compass. 2021 Oct 8;3(2):154-161. doi: 10.1002/bco2.118. eCollection 2022 Mar.
4
The impact of eligibility for maintenance immunotherapy on prognosis in patients with unresectable or metastatic urothelial carcinoma.维持性免疫治疗的 eligibility 对不可切除或转移性尿路上皮癌患者预后的影响。
注：这里“eligibility”直译为“资格”，结合语境不太好理解，推测可能是指符合维持性免疫治疗的条件之类的意思，但按照要求未添加解释。
BJUI Compass. 2021 Oct 8;3(2):139-145. doi: 10.1002/bco2.119. eCollection 2022 Mar.
5
Systematic review of complications arising from male circumcision.男性包皮环切术并发症的系统评价。
BJUI Compass. 2021 Nov 11;3(2):99-123. doi: 10.1002/bco2.123. eCollection 2022 Mar.
6
Long-term outcomes of outpatient laser ablation for recurrent non-muscle invasive bladder cancer: A retrospective cohort study.复发性非肌层浸润性膀胱癌门诊激光消融的长期疗效：一项回顾性队列研究。
BJUI Compass. 2021 Oct 13;3(2):124-129. doi: 10.1002/bco2.120. eCollection 2022 Mar.
7
Mortality in men with castration-resistant prostate cancer-A long-term follow-up of a population-based real-world cohort.去势抵抗性前列腺癌男性患者的死亡率——基于人群的真实世界队列的长期随访
BJUI Compass. 2021 Oct 10;3(2):173-183. doi: 10.1002/bco2.116. eCollection 2022 Mar.
8
Longer preserved urethral length in robot-assisted radical prostatectomy significantly contributes to post-operative urinary continence recovery.机器人辅助根治性前列腺切除术中保留更长的尿道长度对术后尿失禁的恢复有显著作用。
BJUI Compass. 2021 Nov 12;3(2):184-190. doi: 10.1002/bco2.128. eCollection 2022 Mar.
9
Aquablation therapy in large prostates (80-150 cc) for lower urinary tract symptoms due to benign prostatic hyperplasia: WATER II 3-year trial results.用于治疗良性前列腺增生所致下尿路症状的大体积前列腺（80 - 150立方厘米）水消融疗法：WATER II 3年试验结果
BJUI Compass. 2021 Oct 28;3(2):130-138. doi: 10.1002/bco2.121. eCollection 2022 Mar.
10
FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma.FGFR2/3基因改变与转移性尿路上皮癌对恩杂鲁胺的反应
BJUI Compass. 2022 Mar;3(2):169-172. doi: 10.1002/bco2.125. Epub 2021 Nov 10.
Zotero 插件